

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: G. SCHMIDMAIER et al.

Confirmation No.: 8071

Application No.: 09/801,752

Group Art Unit: 1615

Filed: March 9, 2001

Examiner: H. Sheikh

For: BIOLOGICALLY ACTIVE IMPLANTS

Attorney Docket No.: 8932-148

1615
RECEIVED
NOV 14 2003
TECH CENTER 1600/2900

FOURTH INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to applicants' duty of disclosure under 37 C.F.R. § 1.56 and § 1.97(h), enclosed is a substitute Form PTO-1449, entitled "List of References Cited by Applicant, which lists 24 references in reverse chronological order, copies of which are enclosed for the Examiner's convenience. It is respectfully requested that these references be made of record in this application by the Examiner's completion and return of the substitute Form PTO-1449.

As this Information Disclosure Statement is being filed after receipt of the first office action on the merits, but before the mailing date of a final office action or notice of allowance, the fee for this submission pursuant to 37 C.F.R. §1.17(p) is believed to be \$180.00. Please charge this fee and any additionally required fees to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date November 6, 2003

Brian M. Rothery
For: Brian M. Rothery

11/07/2003 CNGUYEN 00000090 161150 09801752
01 FC:1806 180.00 DA


For

Arthur M. Antonelli Reg. No. 51,410
Brian M. Rothery Reg. No. 35,340

PENNIE & EDMONDS LLP
1667 K Street, N.W.
Washington, DC 20006
(202) 496-4400

Enclosures

DC1: 358794.1



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.

8932-148

APPLICATION NO

09/801,752

APPLICANT

G. SCHMIDMAIER et al.

FILING DATE

March 9, 2001

GROUP

1615

RECEIVED
NOV 14 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS


*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,906,600	5/25/1999	Bähr	604	265	
	A02	5,770,255	6/23/1998	Burrell et al.	427	2.1	
	A03	5,759,564	6/2/1998	Milder et al.	424	426	
	A04	5,108,399	4/28/1992	Eitenmuller et al.	606	77	
	A05	4,476,590	10/16/1984	Scales et al.	3	1.91	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION * Abstract Only	
							YES	NO
	B01	EP 0 792 654 A2	9/3/1997	Europe			*X	
	B02	WO 89/04674	6/1/1989	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	F. Kandziora et al., "Experimentelle Spondylodese der Schafshalswirbelsäule," <u>Der Chirurg</u> , 2002, 73:1025-1038.
	C02	M. Lucke et al., "Gentamicin coating of metallic implants reduces implant-related osteomyelitis in rats," <u>Bone</u> , 32 (2003), pp 521-531.
	C03	H. Bail et al., "Systemic application of growth hormone enhances the early healing phase of osteochondral defects-a preliminary study in micropigs," <u>Bone</u> , 32 (2003), pp 457-467.
	C04	G. Schmidmaier et al., "Bone Morphogenetic Protein-2 Coating of Titanium Implants Increases Biomechanical Strength and Accelerates Bone Remodeling in Fracture Treatment: A Biomechanical and Histological Study in Rats," <u>Bone</u> , Vol. 30, No. 6, June 2002:816-822.
	C05	B. Wildemann et al., "Cell Proliferation and Differentiation During Fracture Healing Are Influenced by Locally Applied IGF-1 and TGF- β 1: Comparison of Two Proliferation Markers, PCNA and BrdU," 2003 <u>Wiley Periodicals, Inc.</u> , pp 150-156.
	C06	T. Pufe et al., "Quantitative measurement of the splice variants 120 and 164 of the angiogenic peptide vascular endothelial growth factor iin the time flow of fracture healing: a study in the rat," <u>Cell Tissue Res</u> , (2002) 309:387-392.
	C07	F. Kandziora et al., "IGF-I and TGF- β 1 Application by a Poly-(D,L-Lactide)-Coated Cage Promotes Intervertebral Bone Matrix Formation in the Sheep Cervical Spine," <u>SPINE</u> , Volume 27, Numer 16, pp 1710-1723, 2002.
	C08	F. Kandziora et al., "Bone morphogenetic protein-2 application by a poly(D,L-lactide)-coated interbody cage: in vivo results of a new carrier for growth factors," <u>J Neurosurg (Spine 1)</u> , 97:40-48, 2002.
	C09	G. Schmidmaier et al., "Improvement of Fracture Healing by Systemic Administration of Growth Hormone and Local Application of Insulin-like Growth Factor-1 and Transforming Growth Factor- β 1," <u>Bone</u> , Vol. 31, No. 1, July 2002:165-172.
	C10	F. Kandziora et al., "Bone morphogenetic protein-2 application by a poly(D,L-lactide)-coated interbody cage: in vivo



		results of a new carrier for growth factors," <u>J Neurosurg (Spine 1)</u> 97:40-48, 2002.
	C11	G. Schmidmaier et al., "IGF-1 and TGF-Beta 1 Incorporated in a Poly(D,L-Lactide) Implant Coating Stimulates Osteoblast Differentiation and Collagen-1 Production but Reduces Osteoblast Proliferation in Cell Culture," 2003 <u>Wiley Periodicals, Inc.</u> , pp 157-162.
	C12	M. Raschke et al., "Insulin-like Growth Factor-1 and Transforming Growth Factor- β 1 Accelerates Osteotomy Healing Using Polyactide-coated Implants as a Delivery System: A Biomechanical and Histological Study in Minipigs," <u>Bone</u> , Vol. 30, No. 1, January 2002:144-151.
	C13	M. Raschke et al., "Homologous Growth Hormone Accelerates Healing of Segmental Bone Defects," <u>Bone</u> , Vol. 29, No. 4, October 2001:368-373.
	C14	G. Schmidmaier et al., "A New Electrochemically Graded Hydroxyapatite Coating for Osteosynthetic Implants Promotes Implant Osteointegration in a Rat Model," 2002 <u>John Wiley & Sons, Inc.</u> , pp 168-172.
	C15	F. Kandziora et al., "Comparison of BMP-2 and combined IGF-1/TGF- β 1 application in a sheep cervical spine fusion model," <u>Eur Spine J</u> , (2002), 11:482-493.
	C16	G. Schmidmaier et al., "Local Application of Growth Factors (Insulin-Like Growth Factor-1 and Transforming Growth Factor- β 1) From a Biodegradable Poly(D,L-lactide) Coating of Osteosynthetic Implants Accelerates Fracture Healing in Rats," <u>Bone</u> , Vol. 28, No. 4, April 2001:341-350.
	C17	G. Schmidmaier et al., "Biodegradable Poly(D,L-Lactide) Coating of Implants for Continuous Release of Growth Factors," 2001 <u>John Wiley & Sons, Inc.</u> , pp 449-455.

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED
NOV 14 2003
TECH CENTER 1600/2900